Skip to content

Author

Gui-Jun Ning

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Open access Sep 2026

Immunogenicity and safety of a single dose of adjuvanted RSVPreF3 vaccine in adults ≥60 years of age in China: results from a phase 3 immunobridging trial

Introduction Respiratory syncytial virus (RSV) is an important cause of severe respiratory disease, yet no vaccine is available for older adults in China. This phase 3, randomized, partially blind immunobridging study (NCT06551181) compared a single dose of adjuvanted RSVPreF3 vaccine in ≥60-year-old Chinese adults wit...

Xiang Guo, Gui-Jun Ning, D. Bi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.